Sage Therapeutics' SAGE-718 Gets FDA ODD; Bullish View On TeraWulf
- October 18th, 2023
- 596 views
Shares of Sage Therapeutics, Inc. (Nasdaq: SAGE), a leading biopharmaceutical company specializing in neurological and neuropsychiatric disorders, surged over 5% in pre-market trading after the company said that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to SAGE-718, a potential treatment for Huntington’s disease (HD).
HD, a rare and progressive neurodegenerative condition, impacts an estimated 40,000 U.S. adults annually, with severe cognitive effects.
$SAGE was trading at $21.05 in pre-market, up $1.41 (7.18%).
In other news, Stifel has initiated coverage on TeraWulf Inc. (Nasdaq: WULF), an infrastructure-focused bitcoin mining company, with a Buy rating and set a price target of $3.
Based on Tuesday's closing price of $1.24, the assigned price target implies a potential upside of $1.76 or approximately 141.94% for $WULF, according to the investment banking firm's view.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
NJCP National Football Conference Names David Dalton Head Coach of Salt Lake Yeti
February 06th, 2026FDA Takes New Approach to "No Artificial Colors" Claims
February 06th, 2026NJCP National Football Conference Announces Micah Deckart as Head Coach of the Idaho Outlaws
February 05th, 2026
Member Login